Reach Us +1-504-608-2390
Editor - Collin A Hovinga | University of Tennessee Health Le Bo | 3513
ISSN: 2161-0495

Journal of Clinical Toxicology
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Collin A Hovinga

Collin A Hovinga
Collin A Hovinga
Associate professor
University of Tennessee Health
Le Bonheur Children’s Medical Center
Tel. 901 287 5301
Fax 901 448 6064


Dr. Hovinga completed his Bachelor of Science Degree in Biology (1991) and Doctor of Pharmacy (1997) degrees from Creighton University in Omaha, Nebraska.  After which he pursued a Residency and Fellowship in Pediatric Pharmacotherapy (1997-2000) with emphasis in Pediatric Neuroscience at the University of Tennessee, Memphis, LeBonheur Children’s Medical Center.  He has had a Fellowship at the Food and Drug Administration Office of Clinical Pharmacology (2009) and a Masters of Epidemiology from the University of Tennessee Health Science Center (2010).  He is currently Director of Research at Dell Children’s Medical Center and Associate Professor of Clinical Pharmacy at UT Austin School of Pharmacy. Doctor Hovinga has been active in studying the genetic effects on the susceptibility of neonates to hypoxia-induced seizures and in studying the pharmacogenetics of medications in the treatment of epilepsy and autism.  Dr. Hovinga is recognized as an expert in neuropharmacology.  Dr. Hovinga has had leadership roles in neuroprotective drug pharmacology NIH projects (Clinical Investigations for Neuroprotective Agents in Parkinson’s Syndrome (CINAPS)) and for Huntington’s Disease (SET-HD).  Dr. Hovinga’s understanding of developmental pharmacology and pediatric brain injury has made him unique in the pharmacology arena and has led to him being a journal reviewer and an invited speaker at many national organizational meetings.

Research Interest

Pediatric Pharmacotherapy, Pediatric Neuroscience.



Global Speakers in the subject

Global Experts in the subject